Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415584 | 0.80 | SCN2A (0.51) | SCN2ASCN10ATP53TSHRALDH1A1 | |
| Elpetrigine SCHEMBL978547 | 0.80 | SCN2A (1.00) | SCN2ASCN10AALDH1A1ADORA2APTPN11 | |
| SCHEMBL2421429 | 0.79 | SCN2A (0.57) | SCN2ASCN10AADORA2APTPN11 | |
| SCHEMBL5512633 | 0.78 | SCN2A (0.59) | SCN2ASCN10APTPN11KCNH2 | |
| SCHEMBL3077316 | 0.77 | SCN2A (0.51) | SCN2AAGPAT2ALDH1A1DHFRKDM4E | |
| Elpetrigine SCHEMBL3065529 | 0.75 | SCN2A (0.88) | SCN2ASCN10AADORA2APTPN11KCNH2 | |
| SCHEMBL7059614 | 0.75 | SCN10A (0.53) | SCN2AHTR2BPDE4DSCN10AALDH1A1 | |
| SCHEMBL3701926 | 0.75 | SCN10A (0.57) | SCN2AHTR2BPDE4DSCN10AAGPAT2 | |
| SCHEMBL263262 | 0.74 | SCN10A (0.56) | SCN2AHTR2BPDE4DSCN10AAGPAT2 | |
| SCHEMBL976695 | 0.73 | SCN2A (0.62) | SCN2ASCN10APTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1945630-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| EP-0966448-B1 | PYRAZINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-6599905-B2 | Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-29 | — | — | US | disclosed |
| US-20020169172-A1 | Pyrazine compounds | GLAXO WELLCOME INC. | 2002-11-14 | — | — | US | disclosed |
| US-6255307-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | GLAXO WELLCOME, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0966448-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038174-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | P2RX5, P2RX3, AADAC | SCN2A 44/4885HTR2B 443/4885PDE4D 697/4885 |
| US-20020169172-A1 | Pyrazine compounds | HCRTR1, HCRTR2, GRIN2C | SCN2A 92/4885HTR2B 157/4885PDE4D 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.